Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)

There is no translation available.

Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2)

 

Agents: Surgery & neoadjuvant chemotherapy
Phase III
Status  Open, recruiting
Sponsor EORTC

 

Further information: https://clinicaltrials.gov/ct2/show/NCT04031677 or https://www.eortc.org/research_field/clinical-detail/1809/

This trial to assess whether preoperative chemotherapy followed by surgery improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients.

WHO is the trial for?
  • Patients with high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of the retroperitoneum
    • LMS: Grade 2 and 3, minimum size of tumor 5 cm
    • LPS: All grade 3 dedifferentiated LPS (DDLPS) can be included, grade 2 under certain circumstances
  • The tumor should not have been treated before (no previous surgery (excluding diagnostic biopsy), radiotherapy or systemic therapy)
  • Patient must have radiologically measurable disease (RECIST 1.1)
  • Overall health status of the patient has to be good (WHO performance status ≤ 2)

WHAT is the key question that this trial is attempting to answer?

This study aims to investigate if chemotherapy before surgery (peroperative/neoadjuvant) has a benefit versus surgery alone in patients with leiomyosarcomas or liposarcomas.

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN will the trial be open?

 The study is open (recruiting) for participation.

WHERE is the trial available?

The trial is available in several study centers in Czechia, France, Germany, Italy, Poland, Slovakia, Spain and the UK. For further information please check here: https://www.eortc.org/research_field/clinical-detail/1809/ or https://clinicaltrials.gov/ct2/show/NCT04031677

Study contact: EORTC HQ; +3227741611; Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

STUDY DESIGN: What does the study look like?

All participants will be randomly divided (by a computer) in two groups: One groups receives surgery alone, the other group will be treated with chemotherapy before surgery. 

For LPS, doxorubicin and ifosmomide will be administerd. For LMS, doxorubicin and dacarbacin (DTIC) will be applied as chemotherapy. 

HOW do I get more information?

 Patient organisations supporting sarcoma and/or GIST patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

CONNECT with other patients on this trial

 If you want to connect with other patients considering or participating in this trial, you can find them here.

SHARE your experience

 You want to share your experience on this trial?
Send us an e-mail to: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

 No results are available at this time. Future results will be linked here.


Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken